Director Donnelly Centre for Cellular and Biomolecular Research, and Professor at the University of Toronto, Founder AntlerA Therapeutics,
Joined February 2009
- Tweets4.7K
- Following1.6K
- Followers1.9K
- Likes12.6K
How Trump Is Dismantling America’s Scientific Research Machine nytimes.com/2026/10/31/clima… via @NYTimes
Stephane Angers retweeted
🧠 What if we could help the brain heal after a stroke?
This #WorldStrokeDay, Donnelly researchers are advancing a new approach to stroke recovery, combining enzyme and cell therapies to support brain repair in experimental models of stroke.
🔗thedonnellycentre.utoronto.c…
Stephane Angers retweeted
Donnelly Centre researchers, together with an international team of collaborators, identified hundreds of new microexons and developed a #machinelearning approach that could uncover hidden clues in the #genetics of #Autism.
Read the @Nature study: nature.com/articles/s41586-0…
Stephane Angers retweeted
What could retinal treatment look like five years from now?
At AAO 2026 Retina Subspecialty Day, Drs. Charles Wykoff, Donald D'Amico, and Ehsan Rahimy discussed emerging approaches to retinal disease, from investigational agents including tarcocimab, tabirafusp, and remigromig, to the PRIMA photovoltaic subretinal implant for end-stage geographic atrophy.
Watch the video for the outlook.
For more, visit aao.org/2026.
#aao2026 #retina #aao #retina
Stephane Angers retweeted
🔬Join our interdisciplinary research community and help advance discovery, medicine, and human health!
Recent PhD graduates have until Nov. 3 to apply for the Charles H. Best Postdoctoral Fellowship at #UofT's Donnelly Centre, offering $60K for one year: tinyurl.com/4rv5jdxt
3/4 New mechanism: instead of blocking VEGF, it activates Wnt to repair the blood–retinal barrier. It traces back to our work at @UofT on engineering Wnt-activating antibodies (pubmed.ncbi.nlm.nih.gov/3145…) (pubmed.ncbi.nlm.nih.gov/3410…), then went through AntlerA, EyeBio and Merck.
4/4 Full year-one results come at #AAO2026 on Oct 10, and the BAROLO (DME) and SUPER TUSCAN (nAMD/RVO) trials are ongoing. Grateful to the trainees, collaborators and patients behind this.
2/4 Both doses were non-inferior to ranibizumab in best-corrected visual acuity at week 52. The randomized, double-masked trial enrolled 984 patients.
1/4 Today Merck reported that remigromig (MK-3000, formerly EYE103), a tri-specific Wnt agonist antibody, met its primary endpoint in the pivotal ph. 3 BRUNELLO trial in diabetic macular edema merck.com/news/mercks-remigr…
Stephane Angers retweeted
$MRK's WNT with positive Ph3 data in DME. This is significant as its the first non-VEGF MONOTHERAPY to show success in retina, after steroids. Nice readthrough for $SRZN as its next up with a VEGF/WNT bispecific.
merck.com/news/mercks-remigr…
Stephane Angers retweeted
As a part of our Summer Undergraduate Research Program, 3rd year U of T student Elizabeth Choi has written her first-ever science communications piece: a highlight of Cindi Morshead's career-long investigation into neural stem cells:
thedonnellycentre.utoronto.c…
Stephane Angers retweeted
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work.
We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.
We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
Stephane Angers retweeted
Spanning eight years and over 4,800 experiments, a Hughes Lab global collaboration has concluded with the creation of the Codebook: an enormous database that has illuminated how transcription factors influence human gene regulation:
thedonnellycentre.utoronto.c…
Stephane Angers retweeted
Over 2,000 pathogens engage with the human species in the ever-evolving battlefield of infection and immune defence. To better understand pathogens, the Taipale Lab has built the eORFeome, a scalable genomics screening platform.
thedonnellycentre.utoronto.c…
Stephane Angers retweeted
We are proud to announce the nine graduate students being awarded the 2026 Cecil Yip Doctoral Research Awards!
thedonnellycentre.utoronto.c…
Stephane Angers retweeted
Facinating new Wnt paper published in @PNASNews from the @ClaudioCantu81 group at @liu_universitet explaining how Wnt/β-catenin signaling produces diverse cellular outcomes through TCF7L2/LEF1 binding.
pnas.org/doi/10.1073/pnas.25…
Stephane Angers retweeted
The Donnelly Centre is hiring a Research and Communications Officer! This role covers the external and internal communications of our community: from news stories and social media, to web page management and event support.
jobs.utoronto.ca/job/Toronto…
Stephane Angers retweeted
Just amazing to watch deaths from cervical cancer plummet as HPV vaccination coverage increases
thelancet.com/journals/lance…
